Pasithea Therapeutics Corp. (KTTAW)
- Previous Close
0.0125 - Open
0.0125 - Bid --
- Ask --
- Day's Range
0.0140 - 0.0140 - 52 Week Range
0.0140 - 0.0140 - Volume
8,194 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
www.pasithea.comRecent News: KTTAW
Compare To: KTTAW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KTTAW
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.02%
Return on Equity (ttm)
-47.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.51M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
16.33M
Total Debt/Equity (mrq)
0.35%
Levered Free Cash Flow (ttm)
-7.32M
Company Insights: KTTAW
KTTAW does not have Company Insights